A doctor looked at me after nearly a year of trying three different weight loss medications, Ozempic, Wegovy, and Zepbound, and told me I needed to leave the program. Not because I was unwell. Not because I had done anything wrong. Because I had gained ten pounds on medications designed to produce the opposite result, and that outcome was making their numbers look bad.

I was hurting the data.

I sat with that for a long time. The humiliation of being told that my body, the one that had already been ignored and misread and handed back generic advice for years, was now actively inconvenient. I wasn't a patient who needed a different approach. I was a variable that didn't fit. And the cleanest solution was to remove me from the equation.

It took me a while to understand what had actually happened in that room. And when I did, everything about Brown Body Reset started to make sense.

What Actually Happened with the Medications?

I did not take these medications lightly. I went into the program at my doctor's office with real hope and genuine commitment. The plan was structured. The monitoring was regular. When Ozempic did not produce results, we moved to Wegovy. When Wegovy did not produce results, we moved to Zepbound. Each time, the dose was adjusted upward. Each time, my body responded in the opposite direction from what everyone expected.

Ten pounds gained. Close to a year in. Doctors who had no explanation except that I must be doing something wrong, eating too much, not moving enough, not being consistent enough, even though I was in a monitored program and the numbers were documented. The problem, as far as the program could see, was me.

What nobody said out loud, and what I have since spent considerable time understanding, is that these medications were never tested on a body like mine. The data that produced the protocols I was following, the dosing schedules, the expected outcomes, and the benchmarks for what counts as working were built from a clinical trial population that looked nothing like me.

Were GLP-1 Medications Ever Tested on Brown Bodies?

This is the question I wish someone had asked before I started.

The landmark trials for semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) are among the most widely discussed studies in modern medicine. They produced dramatic results in their trial populations. What the headlines rarely mention is who was in those trials. The trials that produced these results were 79% white, with bodies like mine barely represented in the data. South Asian women, Black women, and Brown women, the populations with the highest rates of metabolic dysfunction and the most to gain from effective treatment, were the populations most absent from the research.

When the trial data is 79% white, the expected outcomes are white outcomes. The dosing protocols are calibrated to white outcomes. The definition of "working" is based on white outcomes. When my body produced a different result, the program did not ask whether the protocol was wrong for my biology. It asked whether I was wrong for the protocol.

I was removed because I was an outlier. But I was only an outlier because the study didn't include enough people like me to know my response wasn't unusual at all. It was just undocumented.

Why Would a Brown Body Gain Weight on Ozempic?

GLP-1 and GIP receptor agonists, the class of drugs these medications belong to, work primarily by slowing gastric emptying, reducing appetite signaling, and improving insulin secretion in response to meals. For the populations they were designed around, this produces meaningful weight loss. The mechanism is real, and the results in those populations are real.

But appetite suppression is only one part of the weight equation. For women like me, the deeper driver was never appetite. It was insulin resistance, cortisol dysregulation, and a metabolic architecture that stores visceral fat differently and develops insulin resistance even at a normal BMI, driven by decades of stress biology and an ancestral metabolic pattern that no GLP-1 drug was designed to address.

When you suppress appetite in a body running on chronic cortisol, you remove one of the few things keeping blood sugar from crashing completely. The body, reading this as a threat, can compensate by holding on to fat more aggressively, not less. This is not a universal response. But for a body with my specific hormonal profile, it was the response. And it was entirely invisible to a program that had never looked for it.

There is also the muscle loss factor that GLP-1 medications are increasingly associated with. A portion of the weight lost in these trials is lean muscle mass, not just fat. For a body already dealing with insulin resistance, losing muscle worsens insulin sensitivity over time, which can accelerate the very metabolic dysfunction the medication was meant to treat. This is one of the reasons long-term GLP-1 outcomes for insulin-resistant Brown and Black bodies need their own research, not borrowed conclusions from a different population.

What Does It Mean to Be Removed for Hurting the Data?

It means the system was not designed to learn from bodies like mine. It was designed to confirm what it already expected to find.

Clinical research has a long history of treating non-white bodies as edge cases, outliers, variables that complicate clean results rather than patients who deserve answers. I did not expect to experience that firsthand in a doctor's office, in the middle of a monitored weight-loss program. I had already written about being told my labs were normal while my body was not, but this was a different category of dismissal. But that is exactly what happened. When my body produced an inconvenient result, the response was not curiosity. It was a removal.

I left that program humiliated. I had done everything I was asked to do. I had been consistent, patient, and honest with every data point. And I was told, in the most clinical language possible, that my body was the problem.

It took time to get from humiliated to something more useful. But that room is part of why BBR exists. If the data was not going to include bodies like mine, I was going to build something that did.

I was not hurting the data. The data had never included me. Those are not the same thing.

What Did I Do After Leaving the Program?

I stopped waiting for the medical system to have an answer for my body and started finding the answers myself.

I went back to the research, not the mainstream wellness research that had been failing me, but the population-specific studies on South Asian metabolic health, the work on cortisol and visceral fat in Brown and Black women, the data on insulin resistance patterns that present differently across ethnicities. The information existed. It was just never in the room when doctors were talking to me.

What I found was that my body's response to those medications was not mysterious. It was predictable, given my specific metabolic profile. Chronic cortisol dysregulation. Insulin resistance architecture specific to South Asian biology. A hormonal environment that those medications were not designed to address, because the populations they were designed around did not share those patterns at the same rate. I wasn't broken. I was just the patient the trials had left out.

Understanding that shifted everything. Not just emotionally, though it did that too. It changed what I looked for, what I tried, and eventually what I built. BBR is the direct result of that research, applied to a body the existing programs had no framework for. You can read more about how the cortisol and stress architecture behind Brown body weight connects to why standard programs miss us entirely.

I do not think GLP-1 medications are without value. For the populations they were designed around, the results are real. But for Brown and Black women with the metabolic profiles that our communities carry in higher numbers, those medications alone are not the answer. And a medical system that removes patients for not fitting the expected outcome is not equipped to find one.

The data did not include me. So I built something that did.

Questions We Hear About Ozempic, Wegovy, and Brown Bodies